VolitionRx (VNRX) to Release Quarterly Earnings on Monday

VolitionRx (NYSEAMERICAN:VNRX) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect VolitionRx to post earnings of ($0.06) per share and revenue of $0.55 million for the quarter.

VolitionRx Stock Performance

Shares of VolitionRx stock opened at $0.50 on Friday. The stock has a 50-day moving average price of $0.52. The stock has a market capitalization of $31.59 million, a P/E ratio of -0.89 and a beta of 1.59. VolitionRx has a 12-month low of $0.42 and a 12-month high of $0.90.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.